Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Multiple Sclerosis

Sanofi reception

Sanofi bolsters pipeline with $3.7bn deal for Principia Biopharma

French drugmaker will gain access to a portfolio of BTK inhibitors

- PMLiVE

Novartis builds its case for novel MS treatment ofatumumab

Detailed results from phase 3 studies published in NEJM

What gets on your nerves?

COUCH Health

- PMLiVE

Biogen triumphs over Mylan’s Tecfidera patent challenge

Shares in Biogen skyrocketed by 32% following ruling

- PMLiVE

Novartis gets EU approval for multiple sclerosis therapy Mayzent

Offers subgroup of patients an important new treatment option

- PMLiVE

Biogen under fire over $88,000 Vumerity annual price

Pricing pressure levelled at Tecfidera follow-up MS drug

- PMLiVE

Sanofi settles Lemtrada dispute with Genzyme investors for $315m

The MS drug has been in decline amid increased market competition

- PMLiVE

New data backs GeNeuro’s MS drug after Servier exit

Search continues for new development partner

- PMLiVE

Merck takes evobrutinib for MS into phase 3, on mixed data

First drug in class to reach this stage for the illness

- PMLiVE

Tecfidera successor’s side-effect profile boosts Biogen

But analysts unconvinced that patients will switch

The role of brain health in treating MS

Blue Latitude Health speaks to Professor Gavin Giovannoni, key opinion leader and Chair of Neurology, Barts and The London School of Medicine and Dentistry, about his theories on brain health,...

Blue Latitude Health

Diagnosing MS: are we getting it right?

Multi-award-winning patient advocate, Trishna Bharadia, walks through the complications involved with an MS diagnosis, including the challenges for healthcare systems and a handful of insightful patient stories.

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links